Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TRMT61B is a mitochondrial RNA methyltransferase enzyme encoded in the nuclear genome but localized primarily in mitochondrial matrix, where it catalyzes the formation of N(1)-methyladenine (m^1A) at position 58 of specific mitochondrial tRNAs and at position 947 of mitochondrial 16S rRNA[1][3]. These methylation events are critical for proper mitoribosome structure, mitochondrial translation, and protein synthesis. Loss of TRMT61B impairs mitochondrial respiration and can decrease tumor cell proliferation, especially in highly aneuploid cancers, linking it to mitochondrial genome regulation and cellular metabolic homeostasis[5]. Elevated expression is associated with tumor aneuploidy, and abnormal TRMT61B levels may play a role in cancer and neurodegenerative disease[1][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on tRNA (adenine(58)-N(1))-methyltransferase, mitochondrial (TRMT61B).